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To determine the efficacy of first-line sequential high-dose VIP chemotherapy (HD-VIP) in patients with primary mediastinal
nonseminomatous germ cell tumours (GCT), 28 patients were enrolled on a German multicentre trial. High-Dose VIP chemotherapy
consisted of 3–4 cycles of dose-intensive etoposide and ifosfamide plus cisplatin, q22days, each cycle followed by autologous
peripheral blood stem cell transplantation plus granulocyte-colony stimulating factor (G-CSF) support. One cycle of standard-dose
VIP was applied to harvest peripheral blood stem cells. Ten patients had mediastinal involvement as the only manifestation (36 %), 18
of 28 patients had additional metastatic sites, such as lung (n¼17; 61%), liver (n¼7; 25%), bone (n¼5; 18%), lymph nodes (n¼3;
11%) and CNS (n¼3; 11%). Median follow-up was 43 months (range, 7–113) for all patients and 52 months (range, 22–113) for
surviving patients. Nineteen of 28 patients obtained a disease-free status; 11 with HD-VIP alone and eight with adjunctive surgery. In
addition, one of the four patients with marker negative partial remission after HD-VIP without resection of residual masses is currently
alive. Two patients developed recurrence of GCT or teratoma. Two patients have died due to an associated haematologic disorder.
The 2-year progression-free survival and overall survival rates are 64 and 68%, respectively. This report represents a subgroup analysis
of 28 patients with mediastinal nonsemina within the German first-line study for ‘poor prognosis’ GCT. Compared to data of an
international database analysis including 253 patients with mediastinal nonseminoma treated with conventional chemotherapy, the
results may indicate that HD-VIP results in an approximately 15% survival improvement.
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Testicular germ cell cancer is the most common malignancy in
men aged between 15 and 35 years (Hartmann et al, 1999, Bosl and
Motzer, 1997). An important subset of germ cell tumours (GCT),
approximately 5–7%, is of extragonadal origin (Collins and Pugh,
1964). In adults, these tumours most commonly arise in the
midline of the body, particularly in the retroperitoneum and the
mediastinum. Conventional cisplatin-based chemotherapy has
demonstrated activity in patients with extragonadal GCT, and
long-term survival rates approach those of patients with advanced-
stage metastatic gonadal GCT (Nichols et al, 1990b, Hidalgo et al,
1997). Primary nonseminomatous tumours of the mediastinum
have a poor outcome with conventional chemotherapy and the
presence of a mediastinal location defines the patient as ‘poor
prognosis’ according to the IGCCCG classification irrespective of
additional metastatic sites or elevated tumour marker concentra-
tions (Ulbright et al, 1984; Toner et al, 1991; Bukowski et al, 1993;
Childs et al, 1993; Harding et al, 1993; Saxman et al, 1994; Hidalgo
et al, 1997; International Germ Cell Consensus Classification, 1997;
Ganjoo et al, 2000). High-dose chemotherapy with autologous
peripheral blood stem cell transplantation (HD-CT) is used as a
therapeutic option with acceptable toxicity in patients with
relapsed GCT, and has also been investigated as first-line therapy
in patients fulfilling ‘intermediate’ or ‘poor prognosis’ criteria
according to the IGCCCG classification (Motzer et al, 1993, 1997;
Bokemeyer et al, 1998). A retrospective matched-pair analysis
demonstrated that first-line HD-CT is associated with a potential
survival benefit of approximately 15% at 2 years in ‘poor
prognosis’ patients compared to standard-dose cisplatin-based
chemotherapy (Bokemeyer et al, 1999). This report summarises
our experience with HD-CT in patients with mediastinal non-
seminomatous GCT. Those patients were included into a German
multicentre trial using HD-VIP regimen as first-line treatment in
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lpatients fulfilling either ‘advanced disease’ criteria according to the
Indiana classification or IGCCCG ‘poor prognosis’ criteria since its
introduction in 1995 (Birch et al, 1986; International Germ Cell
Consensus Classification, 1997).
PATIENTS AND METHODS
From January 1993 to July 1998, 28 patients with primary
mediastinal nonseminomatous GCT were treated with sequential
first-line HD-VIP chemotherapy followed by autologous peripheral
blood stem cell transplantation within a German prospective,
multicentre trial. Eligibility criteria included nonseminomatous
histology, any primary site, ‘advanced disease’ according to the
Indiana University Criteria (Birch et al, 1986) or ‘poor prognosis’
according to the IGCCCG (International Germ Cell Consensus
Classification, 1997), adequate kidney function (creatinine clear-
ance 460mlmin
 1) and liver function (bilirubin o1.5-fold upper
normal limit, liver enzymes othree-fold upper normal limit), no
prior chemotherapy as well as informed consent. The local ethical
committee had approved the study. Treatment consisted of one
cycle of standard-dose VIP-chemotherapy (cisplatin 20mgm
 2,
etoposide 75mgm
 2, ifosfamide 1200mgm
 2, daily for 5 days)
plus granulocyte-colony stimulating factor (G-CSF) 5mgkg
 1
starting at day 7 followed by peripheral blood stem cell collection
and subsequently three sequential cycles of HD-VIP chemother-
apy. Another HD-VIP cycle was allowed in case of declining but
not completely normalised tumour marker concentrations. The
dosages of the high-dose cycles were escalated over six different
patient cohorts. No intraindividual dose escalation was performed.
Data on the treatment protocol have been reported elsewhere
(Bokemeyer et al, 1998). The dosages applied ranged from 200 to
350mgm
 2 for etoposide, 1.6–2.4gm
 2 ifosfamide and cisplatin
20 (levels 4–6) to 30mgm
 2 (levels 1–3) daily for five consecutive
days every 3 week. All patients received autologous peripheral
blood stem cell transplantation (at least 1 10
6 CD 34þ cellskg
 1
body weight) at day 7 after every 5-day HD-VIP application as well
as 5mgkg
 1 body weight G-CSF (filgrastim) support subcuta-
neously starting 24h after completion of chemotherapy (for details
see Figure 1). All patients have been analysed on an intention-to-
treat principle. An extragonadal mediastinal GCT by definition
required the absence of testicular abnormalities on physical
examination and ultrasonography. In case of testicular abnorm-
alities, biopsy was performed to exclude invasive testicular germ
cell cancer. Testicular intraepithelial neoplasia or a scar found at
biopsy was not a cause for exclusion from study. Resection of
residual tumour masses after chemotherapy was planned, if
technically feasible, for all patients with marker negative partial
remission (PR) or in patients with still decreasing but not
completely normalised markers and partial radiological responses.
Resected specimens were categorised according to the following
criteria: necrosis referred to findings of necrotic debris only in the
resected specimen. Differentiated teratoma referred to the finding
of mature teratoma in the absence of either malignant transforma-
tion or GCT such as embryonal carcinoma, yolk sac carcinoma,
choriocarcinoma or seminoma. Any of the latter histological
findings were considered as vital tumour as well as teratoma with
malignant transformation. In case of a complete resection of all
residual masses, patients were categorised depending on the
histological results as no evidence of disease (NED) (either vital
tumour, differentiated teratoma or necrosis). However, in four
patients who had attained serologic complete remission (CR) but
had persistent minor radiographic abnormalities, individual
investigators have chosen to observe such patients without surgery
because of nonresectability. Those patients were formally coded as
PR in the follow-up status if their residual abnormalities remained
stable or decreased on imaging studies over a 1-year period.
A CR was defined as the complete disappearance of all clinical,
radiological and biochemical evidence of disease after chemother-
apy. Marker negative partial remission (PRm-) was assumed in
patients with any decrease in the sum of the products of diameters
of measurable lesions and normalisation of tumour markers.
Progressive disease (PD) was defined as either residual lesions
increasing in size or occurrence of new lesions and/or elevation of
tumour markers at repeated controls.
Statistical analysis
Statistical analysis was performed using SPSS (SPSS for Windows
10.0. software SPPS Inc., Chicago, IL, USA). For all living patients,
the status as of January 2002 was obtained. The overall survival
(OS) calculation used death due to any reason as the end point.
Various patients’ characteristics such as, categorial variables,
extent of disease at diagnosis, evidence of bone, lung, liver, brain,
lymph node involvement, age grouping or tumour marker
grouping (according to the IGCCCG classification) were investi-
gated as potential prognostic factors by univariate analysis. For the
survival time, the proportion of survivors was estimated by the
Kaplan–Meier method (Kaplan and Meier, 1958), and the log-rank
test was used for comparison. For ordered categorial variables, the
log-rank test for trends was used. All factors with a P-value o0.05
were considered as significant. All reported P-values were two-
sided.
The survival data of patients with high-dose chemotherapy have
been compared with the cohort of patients receiving cisplatin-
based conventional dose chemotherapy available from the Inter-
national Extragonadal Germ Cell Tumour Study Group, which
comprised individual treatment data on 635 patients with
extragonadal GCT from 11 European and US cancer centres
(Bokemeyer et al, 2002; Hartmann et al, 2002). A small proportion
of patients with conventional dose chemotherapy received double-
dose cisplatin, which had no impact on efficacy in a randomised,
prospective intergroup study (Nichols et al, 1991).
RESULTS
Patients’ characteristics
Twenty-eight patients with primary mediastinal nonseminomatous
GCT were treated within the HD-VIP protocol from 1993 to 1998.
The median age was 32 years (range, 20–50). A detailed list of the
patients’ characteristics is given in Table 1. Due to the presence of
the primary mediastinal GCT, all patients were classified as ‘poor
prognosis’ testicular germ cell cancer according to the IGCCCG
Dose level (mg m−2 per cycle)
12 3 4 56
V (etoposide) 1000 1000 1250 1500 1500 1750
I (ifosfamide) 8000 10000 10000 10000 12000 120000
P (cisplatin) 150 150 150 100 100 100
PBSC-
harvest PBSCT PBSCT PBSCT
facultative*
SD-
VIP G-CSF
HD-
VIP G-CSF
HD-
VIP G-CSF
HD-
VIP G-CSF
HD-
VIP
Cycles were given in 21 day intervals
Figure 1 Design of sequential HD-VIP with PBSCT. SD¼standard dose;
HD¼high dose; G-CSF¼granulocyte-colony-stimulating factor;
PBSC(T)¼autologous peripheral blood stem cell (transplantation). *Five
patients received a 4th HD-VIP cycle because of declining, but not
completely normalised, tumour maker concentrations.
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18 patients (64%) fulfilled ‘poor prognosis’ criteria either because
of the additional presence of visceral metastases or ‘poor marker’
status. Serum concentrations of the tumour markers a-fetoprotein,
b-human chorionic gonadotropin and lactate dehydrogenase were
elevated in 61, 36 and 43% of the 28 patients, respectively. Ten
patients had localized disease confined to the mediastinum (36%),
seven (25%) had additional thoracic involvement and 11 patients
(39%) had evidence of visceral disease.
Treatment side effects
A total of 89 high-dose cycles with a median number of 3 (range,
3–4) per patient were given to the 28 patients with mediastinal
primary tumours resulting in a median duration of WHO grade IV
granulo- and thrombocytopenia of 6 and 4 days. Median time to
haematologic recovery from the start of treatment was at days 15
and 16, respectively. WHO grade III/IV mucositis/enteritis
occurred in nine (32%) patients. Nine (32%) patients developed
grade III/IV fever/infection. No toxic death occurred. Chemother-
apy-related neurotoxicity grade I/II was observed in five (18%)
patients.
Response to treatment
Median follow-up duration was 43 months (range, 7–113) for all
patients and 52 months (range, 22–113) for surviving patients.
Follow-up data and response evaluation are summarised in Table 2.
Nineteen of 28 patients (68%) obtained a disease-free status after
treatment. Of the 19 patients with no evidence of disease after
treatment, 16 are continuously in CR and in addition, one of four
patients with PRm- after HD-VIP is currently alive. Two patients
have relapsed from CR with recurrent GCT (n¼1) and teratoma
(n¼1). Relapses occurred after 32 and 43 months after treatment.
The patient who had developed teratoma remained alive and
disease free 37 months after mediastinal resection and atypical
right upper lobectomy. Three of four patients relapsed after
achievement of a marker normalised PR at 2, 5 and 10 months after
completion of chemotherapy. Two patients developed haematolo-
gic disorders, one an acute myelogenous leukaemia and the other a
myelodysplasia with abnormal megakaryocytes, 12 and 18 months
after initial therapy. Both died shortly after the occurrence of the
haematologic disorder. Patients, who did not attain a CR to HD-
VIP, received different second-line chemotherapy regimens
including VeIP (Loehrer et al, 1998), TIP (Rick et al, 2001),
continuation of standard VIP and oral etoposide; however, none of
the patients responded to salvage treatment. Neither the median
progression-free survival (PFS) nor the median OS has been
reached. The estimated 2- and 5-year PFS rates are 64% (95 % CI,
47–82%) and 56% (95% CI, 37–75%), and the estimated OS rates
are 68% (95% CI, 51–85%) at 2 years and 64% (95% CI, 46–82%)
at 5 years.
Univariate analysis on prognostic factors for survival
Results are summarised in Table 3. A significant inferior PFS was
found for patients who had a disease extending beyond the
mediastinum with evidence of liver or pulmonary metastases.
Disease confined to the mediastinum indicated a superior
Table 1 Characteristics of 28 patients with nonseminomatous mediast-
inal GCT
Characteristics No. of pts %
Median age – years (range) 32 (20–50) –
Histology
Nonseminomatous GCT
a 28
b 100
Teratocarcinoma 4 14
Endodermal sinus tumour 8 29
Choriocarcinoma 8 29
Embryonal Cell 1 4
Serologic diagnosis only
c 14
other GCT histology 6 21
Elevated serum tumour markers
a-fetoprotein 17 61
Median (range) in ngml
 1 912 (1 to 31.114)
Human chorionic gonadotropin 10 36
Median (range) in mIUml
 1 34 (0.9 to 300.000)
Lactate dehydrogenase 12 43
Median (range) in IUl
 1 360 (113 to 2.682)
Extent of disease
Localised mediastinal mass 10 32
Additional lung/pleural involvement 7 25
Visceral metastases 11 39
Sites of metastases
Bone 5 18
Lung 17 61
Liver 7 25
CNS 3 11
LN 3 11
Other 5 18
Previous chemotherapy – –
aGCT¼germ cell tumour;
bA total of 12 of 28 patients have been included in
Bokemeyer et al (1998);
cPatient had a mediastinal mass without histologic diagnosis
of the tumour and elevation of tumour marker concentrations b-HCG and/or AFP
indicating a mediastinal nonseminomatous GCT.
Table 2 Response to treatment and current follow-up status
No. of pts %
Response to treatment
a
CR/NEDnecrosis 11 (4
b/7) 39 (14/25)
NEDvital tumour 7
c 25
NEDteratoma 14
PRm  41 4
PD 5 18
Follow-up status
NED 17
d 61
Continuously NED 16 57
PR (41 year) 1 4
DoD 8 29
Dead due to haematologic disorder 2
e 7
Estimated OS % CI95%
At 2 years 68 51–85
At 5 years 64 46–82
Estimated PFS
At 2 years 64 47–82
At 5 years 56 37–75
aEvaluation of response based on CT scans and determination of serum tumour
marker concentrations.
bIncluding one patient with consolidation CNS radiation for
CNS metastases.
cOne patient with non-germ cell tumour elements.
dOne patient
after resection of mature teratoma at relapse.
eOne patient with simultaneous relapse
of GCT (after achievement of PRm ) and development of haematologic disorder
(myelodysplasia with abnormal megakaryocyctes). CR¼complete remission after
chemotherapy alone; NEDvital tumour/teratoma/necrosis¼no evidence of disease after
complete resection of vital tumour or differentiated teratoma; PR¼partial remission;
PD¼Progressive disease; DoD¼dead of disease; CI¼confidence interval;
OS¼overall survival; PFS¼progression-free survival; pts¼patients.
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loutcome. The presence of liver metastases was identified to worsen
OS. Elevation of tumour marker concentrations and categorisation
into ‘good/intermediate’– vs ‘poor’ – marker according to the
IGCCCG did not influence either PFS or OS.
Comparison to standard-dose cisplatin-containing
treatment programmes
Two hundred fifty three patients with mediastinal GCT, who had
received cisplatin-based conventional chemotherapy between 1979
and 1996, were available from the database of the International
Extragonadal Germ Cell Tumour Study Group comprising 635
patients with extragonadal GCT from 11 cancer centres in the US
and Europe (Bokemeyer et al, 2002; Hartmann et al, 2002). The
results of patients with nonseminomatous mediastinal GCT
undergoing standard-dose regimen were compared with our
experience in patients with dose-intensive chemotherapy accord-
ing to the HD-VIP protocol (Table 4, Figures 2A,B). There was a
higher 5-year OS rate with dose-intensive therapy compared to
standard-dose cisplatin protocols of 64% vs 46% as well as 57% vs
42% for PFS rates at 5 years. The corresponding hazard ratios for
PFS and OS in patients receiving HD-VIP compared to standard
cisplatin chemotherapy were 0.67 (95% CI, 0.42 – 1.17) and 0.59
(95% CI, 0.38 – 1.01), respectively.
DISCUSSION
Although the principles of management of patients with mediast-
inal nonseminomatous GCT parallel those of metastatic nonsemi-
nomatous testicular GCT, patients with mediastinal primaries
clearly have a worse prognosis compared to patients with gonadal
GCT. Accordingly, the presence of a mediastinal primary tumour
in patients with nonseminomatous GCT was identified as a major
adverse prognostic factor by the IGCCCG. Such patients appear to
represent a clinically and biologically distinct disease entity
(Nichols et al, 1985, 1987, 1990a; Hartmann et al, 2000b,
Table 3 Univariate analysis of patients’ and treatment characteristics for their influence on OS in
nonseminomatous mediastinal GCT
Characteristics
No. of
pts (%)
Calculated 5-year
OS rate (%) P
Calculated 5-year
PFS rate (%) P
Extent of disease
Mediastinum only 10 (32) 90 90
Lung/pleural 7 (25) 57 29
Visceral disease 11 (36) 45 0.08 45 0.02
Bone metastases
No 23 (82) 64 59
Yes 5 (18) 60 0.87 60 0.93
Lung metastases
No 11 (39) 89 89
Yes 17 (61) 53 0.23 41 0.03
CNS metastases
No 25 (89) 58 54
Yes 3 (11) 100 0.22 100 0.18
Liver metastases
No 21 (75) 80 75
Yes 7 (25) 14 o0.01 14 o0.01
Lymph nodes
1
No 25 (89) 66 63
Yes 3 (11) 33 0.12 33 0.38
Age
20–25 6 (21) 0 0
26–30 7 (25) 86 86
31–35 7 (25) 57 43
36–40 5 (18) 80 80
440 3 (11) 100 0.02 67 0.27
Tumour marker status
2
AFP
Good/intermediate 18 (64) 67 56
Poor 7 (25) 57 0.65 57 0.87
b-HCG
Good/intermediate 20 (71) 65 60
Poor 5 (18) 60 0.86 40 0.37
LDH
Good/intermediate 24 (86) 67 58
Poor 1 ( 4) 0 0.14 0 0.29
1Additional regional lymph node involvement outside of the midline.
2According to International germ cell consensus
classification, 1997. b-HCG¼beta human chorionic gonadotropin; LDH¼lactate dehydrogenase; LN¼lymph nodes;
OS¼overall survival; PFS¼progression-free survival; pts¼patients.
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l2001a,b), associated with lower complete response rates to
chemotherapy, high rates of relapse and more frequent failures
to salvage chemotherapy (Saxman et al, 1994, Loehrer et al, 1998;
Hartmann et al, 2001a). Historically, the incorporation of cisplatin
into chemotherapy regimens has yielded survival rates of
approximately 30–40% in retrospective analyses (Garnick et al,
1983; Logothetis et al, 1985; Delgado et al, 1993; Dulmet et al, 1993;
Toner et al, 1991; International germ cell consensus classification,
1997). Two prospective series based on 31 and 41 patients reported
a long-term survival rate of 450% following conventional
cisplatin-based chemotherapy plus secondary surgery (Nichols
et al, 1990b, Bukowski et al, 1993). The database of the
International Extragonadal Germ Cell Tumour Study Group
contains 287 patients with primary mediastinal tumour location
and nonseminomatous histology from 11 Cancer Centres (Boke-
meyer et al, 2002; Hartmann et al, 2002). Of these patients, 253
have been treated with conventional cisplatin-based chemother-
apy. The 2- and 5-year OS rates of those patients were 55 and 46%,
and 47 and 42% for PFS.
The analysis of the International Extragonadal Germ Cell
Tumour Study Group demonstrated that patients with primary
mediastinal GCT have a heterogeneous prognosis depending on
patients’ characteristics (Hartmann et al, 2002). Patients having
localised mediastinal disease without elevation of HCG at initial
diagnosis and who were of young age, revealed a favourable
survival (OS 83% at 2 years) compared to patients presenting with
adverse prognostic variables such as presence of visceral
metastases or of lung metastases (OS 34 or 42% at 2 years). One
conclusion from this investigation is that patients with localised
disease confined to the mediastinum have an acceptable prognosis
when treated by a multidisciplinary approach with aggressive
surgery of the residual mediastinal tumour mass.
However, more than half of the patients with mediastinal
nonseminomatous GCT failed to achieve a durable response to
conventional cisplatin-based chemotherapy. The success of
carboplatin/etoposide- (CE) or carboplatin/etoposide/cyclopho-
sphamide- (CEC) containing high-dose chemotherapy with auto-
logous peripheral blood stem cell transplantation (HD-CT) in the
treatment of patients with relapsed disease led to its investigation
as initial first-line treatment in patients fulfilling ‘poor prognosis’
criteria. With this approach as initial treatment, the time to blood
count recovery is shorter, toxicity is reduced, and further dose
intensification is feasible compared with its use in heavily
pretreated patients (Motzer et al, 1996). Two consecutive trials
conducted by investigators at the MSKCC suggested a therapeutic
Table 4 Comparison of trials in patients with primary mediastinal
nonseminomatous GST including conventional cisplatin-based regimen and
high-dose chemotherapy
Conventional dose
a HD-VIP
Variable No. of pts % No. of pts %
Patients 253 28
CR/PRm- (assessable) 157 (244) 45 17 (28) 61
Status
NED 114 45 17 61
AwD 11 4 1 4
Dead 121 48 10 36
Lost to follow-up 9 4 – –
Median 5-year PFS rate (%) 42 56
Median 5-year OS rate (%) 46 64
Median PFS (months) 15 Not reached
Median OS (months) 40 Not reached
HD¼high dose; CR¼complete remission; PRm-¼marker normalized partial
remission; NED¼no evidence of disease; AwD¼alive with disease; PFS¼progres-
progression-free survival; OS¼overall survival; pts¼patients.
aData about patients
receiving standard cisplatin chemotherapy are derived from the database of the
International Extragonadal Germ Cell Tumour Study Group (in part described in
Bokemeyer et al, 2002, Hartmann et al, 2002).
Patients at risk median OS (mos)
HD-VIP 28 24 19 16 12 8 −
Standard cisplatin 253 174 113 80 66 53 40
HR: 0.59 (95% CI, 0.38 – 1.01) 
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Patients at risk median PFS (mos)
HD-VIP 28 21 18 15 11 8 −
Standard cisplatin 251 127 89 68 53 40 15
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Figure 2 Overall survival (A) and PFS (B) for patients with primary
mediastinal nonseminoma treated on programmes that included either
high-dose chemotherapy (HD-VIP) or conventional dose cisplatin-based
combination chemotherapy (date about patients receiving standard
cisplatin chemotherapy are derived from the database of the International
Extragonadal Germ Cell Tumour Study Group (in part described in
Bokemeyer et al, 2002; Hartmann et al, 2002). mos¼ months
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lbenefit for HD-CT when used as first-line treatment for ‘poor
prognosis’ patients (Motzer et al, 1993, 1997). The long-term
survival rates for all ‘poor prognosis’ patients have been 54 and
67% after HD-CT with the CE- or CEC-regimen. These trials
included single patients with primary mediastinal nonseminoma-
tous GCT; however, no detailed data on response and outcome for
this subgroup of patients due to the small numbers were reported.
The use of initial dose intensification in patients with non-
seminomatous mediastinal GCT appears reasonable because the
results with salvage treatment, even including HD-CT, have been
rather disappointing. It appears that more than 90% of patients with
relapsed mediastinal nonseminoma fail to obtain a durable,
complete remission in the salvage setting (Josefsen et al, 1993;
Saxman et al, 1994; Loehrer et al, 1998; Hartmann et al,2 0 0 1 a ) .
The current series on the use of intensive first-line HD-VIP for
patients with primary mediastinal nonseminoma indicates the
feasibility of this approach, and a 15–20% absolute survival
improvement for these patients receiving sequential HD-VIP as
initial treatment compared to the use of conventional induction
chemotherapy might be achievable. Calculation of the hazard
ratios portended a 33% and 41%-risk reduction in recurrence and
death probability for patients treated with HD-VIP compared to
standard cisplatin chemotherapy. However, this is based on a small
sample size in the high-dose chemotherapy group. The compar-
ison of high-dose and standard-dose chemotherapy was not
performed as a prospective randomised trial, and therefore patient
selection and stage migration might be an issue since both groups
of patients had been treated in a different time period.
Prognostic factors for patients receiving HD-VIP in the
univariate analysis have been similar to those in the International
Extragonadal Germ Cell Tumour Study Group database – localised
mediastinal disease vs visceral disease, for example, liver, bone,
CNS metastases and lung/pleural involvement. The OS rates at 2
years achieved in this investigation compared to the expected rates
according to the prognostic index of the International
Extragonadal Germ Cell Tumour Study Group for mediastinal
nonseminomas have been 100 vs 65% for patients with localised
disease, 57 vs 42% for disease confined to the thorax (patients
with lung or pleural metastases) and 45 vs 34% for patients with
presence of visceral metastases (Hartmann et al, 2002), suggesting
that the results observed in this investigation of dose-intensified
HD-VIP chemotherapy might not be achieved due to a
selection of patients possessing more favourable prognostic
characteristics. The only way to truly ascertain the difference
between standard- and high-dose chemotherapy is to perform a
randomised trial. An ongoing phase III trial has been initiated in
the US to define the role of HD-CT including high-dose
carboplatin instead of cisplatin in ‘intermediate’ and ‘poor
prognosis’ patients. This trial also includes patients with primary
mediastinal nonseminoma. However, because of the rarity of
mediastinal location within the group of poor prognosis patients,
this trial will only include approximately 12–18 patients with
primary mediastinal GCT in each arm that will not allow a
sufficient subgroup analysis.
Overall, the survival rates in patients with mediastinal GCT have
been improved over the years – particularly due to aggressive
postchemotherapy surgery of residual mediastinal masses – now
approaching the rate which is achieved in patients with ‘poor
prognosis’ metastatic disease according to the IGCCCG classifica-
tion (International Germ Cell Consensus Classification, 1997).
More than half of the patients in the current series have undergone
a multidisciplinary treatment approach including aggressive
postchemotherapy surgery and the use of consolidation radiation
of the brain in one patient. As in patients with metastatic gonadal
GCT, radical surgical resection of residual masses after first-line
chemotherapy is indicated, whenever technically possible either as
a one-stage or as a sequential procedure (Kay et al, 1987; Wright
et al, 1990; Nichols et al, 1990b; Hartmann et al, 1997; Ganjoo et al,
2000; Vuky et al, 2001). In this series, all 10 patients with disease
confined to the mediastinum regardless of other prognostic factors
that are relevant for metastastic gonadal GCT, for example, tumour
marker status, are disease-free. One of these patients died due to a
haematologic disorder without evidence of GCT relapse.
As described before, there is approximately a 6% risk to develop
a haematologic disorder in patients with primary mediastinal
nonseminoma, which represents a biological phenomenon not
related to chemotherapy (Nichols et al, 1985, 1990a; Hartmann
et al, 2000b). The haematologic malignancies have a very
aggressive clinical course with patients either dying before
treatment, not responding to antileukaemic therapy, or achieving
remissions of very short duration. In the current investigation, two
patients died due to haematologic disorders 12 and 18 months
after completion of GCT treatment.
Investigational approaches in progress explore whether the
outcome of patients with mediastinal primary GCT can be further
improved with the use of first-line sequential HD-CT or with the
addition of further active drugs to the HD-VIP regimen (Hartmann
et al, 2001c). In order to improve the prognosis of patients with
mediastial GCT, it appears mandatory to include these patients
into controlled clinical trials at experienced centres.
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APPENDIX
Additional participating institutions: W-E Aulitzky, Robert-Bosch-
Krankenhaus Stuttgart, G Derigs, Universita ¨tsklinik Mainz; M de
Wit, UKE Hamburg; CH Ko ¨hne, Universita ¨t Dresden; K-H Pflu ¨ger,
Diakonissenkrankenhaus Bremen; M Sosada, Siloah-Krankenhaus
Hannover; N Frickhofen, HSK-Klinik Wiesbaden; J Schleicher,
Katharinenhospital Stuttgart, Germany.
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